Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 16INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Classical hematology 1

Conditions

Solid Tumor 1Chemotherapy-Induced Febrile Neutropenia 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Long-Term Synaptic Depression × Clear all
NCT06711523 2025-11-25

Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

Kexing Biopharm Co., Ltd.

Phase 3 Active not recruiting
250 enrolled
Classical hematology

Chemotherapy-Induced Febrile Neutropenia

NCT07030439 2025-06-22

A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State

Impact Therapeutics, Inc.

Phase 1 Completed
32 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡